- Report
- April 2023
- 160 Pages
Global
From €4534EUR$4,949USD£3,853GBP
- Report
- April 2023
- 147 Pages
Global
From €4534EUR$4,949USD£3,853GBP
- Report
- November 2023
- 353 Pages
Global
From €8703EUR$9,500USD£7,396GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2519EUR$2,750USD£2,141GBP
- Report
- October 2023
- 189 Pages
Global
From €4122EUR$4,500USD£3,504GBP
- Report
- October 2021
- 54 Pages
Global
From €2290EUR$2,500USD£1,946GBP
- Report
- October 2024
- 80 Pages
Global
From €3500EUR$4,093USD£3,079GBP
- Report
- March 2024
- 71 Pages
Global
From €3500EUR$4,093USD£3,079GBP
- Report
- February 2024
- 85 Pages
Global
From €3500EUR$4,093USD£3,079GBP
- Report
- February 2024
- 90 Pages
Global
From €3500EUR$4,093USD£3,079GBP
- Report
- December 2022
- 82 Pages
Global
From €1832EUR$2,000USD£1,557GBP
- Report
- October 2022
- 138 Pages
Global
From €1832EUR$2,000USD£1,557GBP
- Report
- May 2025
- 50 Pages
Global
From €2428EUR$2,650USD£2,063GBP
- Report
- October 2024
Global
From €3206EUR$3,500USD£2,725GBP
Everolimus is a drug used in the treatment of breast cancer. It is an mTOR inhibitor, which works by blocking the activity of a protein that helps cancer cells grow and divide. It is used in combination with other drugs to treat advanced or metastatic breast cancer. Everolimus is also used to treat hormone receptor-positive, HER2-negative breast cancer that has spread to other parts of the body. It is typically used in combination with other drugs, such as letrozole or fulvestrant.
Everolimus is available in tablet form and is taken orally. It is usually taken once daily, with or without food. Common side effects of Everolimus include nausea, vomiting, diarrhea, fatigue, and mouth sores.
In the Everolimus market, some of the major players include Novartis, Pfizer, AstraZeneca, and Merck. Other companies involved in the market include Amgen, Teva Pharmaceuticals, and Eli Lilly. Show Less Read more
